Eli de los Pinos is the founding CEO of Aura, which she has created from the ground up. Prior to founding Aura, she worked in Eli Lilly & Co.’s oncology business unit, where she was part of the leadership team responsible for the market launch in Europe of Alimta, a drug for the treatment of lung cancer. Earlier in her career, Eli worked as a post-doctoral fellow at the Institute of Cancer Research in London. She previously completed fellowships at the Mount Sinai School of Medicine Institute of Molecular Medicine and at the Georgetown School of Medicine. Eli holds a Ph.D., magna cum laude, in Molecular Biology from the University of Barcelona and an MBA from IE Business School.